Abstracts of the 2023 Annual Meeting of the ALEH
More infoNo
Introduction and ObjectivesTransient elastography (TE) is an alternative diagnostic tool for estimating liver steatosis and fibrosis. Two ET devices, iLivTouch®/UAP and Fibroscan®/CAP, have shown similar diagnostic accuracy; however, no studies have evaluated the correlation of liver steatosis and fibrosis measurements between both devices in the Mexican population. Aim: To evaluate the correlation of measurement values of liver steatosis and liver fibrosis using iLivTouch®/UAP and Fibroscan®/CAP.
Patients / Materials and MethodsThis prospective study included adult patients who attended a check-up unit. The evaluation of liver steatosis and liver fibrosis was performed using TE with two devices (iLivTouch® FT100 and Fibroscan® 502 Touch), meeting the reliability parameters. The correlation of measurements was evaluated with the Pearson correlation coefficient; meanwhile, a Student's t-test was performed to determine differences in dB/m and kPa means.
Results and DiscussionA total of 69 patients were included; 57% (n=40) were men, with a mean age and body mass index of 45±10 years and 22.4±4.5 kg/m2, respectively. The prevalence of diabetes mellitus was 7.2% (n=5). The mean dB/m and kPa were 266±42 dB/m and 5.8±1.2 kPa with iLivTouch® and 243±56 dB/m and 4.0±0.8 kPa with Fibroscan®. The prevalence of liver steatosis was 29% (n=20) by iLivTouch® and 20% (n=14) by Fibroscan® (p=0.32), while fibrosis was 49.3% (n=34) and 2.9%. (n=2), respectively, (p=0.0001). The mean difference for dB/m was -22.6, p≤0.0001, while for kPa, the difference was 1.72, p≤0.0001. According to the correlation analysis, this was r=0.73 (strong), p≤0.0001 for the estimation of liver steatosis, and r=0.35 (moderate), p=0.003 for the estimation of liver fibrosis.
ConclusionsTE devices iLivTouch® and Fibroscan® show a strong correlation for estimating liver steatosis and a moderate correlation for estimating liver fibrosis.
